2seventy bio-partnered Abecma (idecabtagene vicleucel) is already approved as a fourth-line or later therapy for the blood cancer, and the KarMMa-3 study is designed to support second or third ...

Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy for multiple myeloma ...

The voting on Abecma comes after Johnson & Johnson and Legend Biotech won unanimous AdCom backing for a similar label expansion for their CAR-T therapy Carvykti on Friday. More on Bristol-Myers ...

He noted that the company's focus on Abecma has positioned them to potentially reach quarterly breakeven by the end of 2025. The company's financial position includes approximately $184 million in ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers ...